- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06392295
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer (OCEAN)
A Phase II Trial of PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer - The OCEAN Trial
The purpose of this prostate cancer research study is to learn about:
- Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy;
- Preserving quality of life after radiation therapy;
- Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.
Study Overview
Status
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Benjamin J Rich, MD
- Phone Number: 305-243-4200
- Email: brich@miami.edu
Study Contact Backup
- Name: Alan Dal Pra, MD
- Phone Number: 305-243-4200
- Email: alan.dalpra@med.miami.edu
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
Principal Investigator:
- Alan Dal Pra, MD
-
Contact:
- Benjamin J Rich, MD
- Phone Number: 305-243-4200
- Email: brich@miami.edu
-
Principal Investigator:
- Benjamin J Rich, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically proven prostate adenocarcinoma
- Male, ≥ 18 years old
Oligorecurrent disease limited to the sub-diaphragmatic region with or without pelvic lymph nodes
- a. No more than a total of 5 lesions on PSMA PET/CT scan (each lesion defined as positive with standardized uptake value (SUV) > liver uptake and CT scan correlate)
- b. No disease outside of the pelvic and sub-diaphragmatic para-aortic lymph nodes
- c. At least one lesion in the sub-diaphragmatic para-aortic lymph nodes
- d. Non-bulky nodal disease (ie, tumor <5 cm)
Prior pelvic radiation with disease response
- a. Definitive radiation therapy to the prostate with or without treatment of the pelvic lymph nodes and/or
- b. Salvage or adjuvant radiation therapy to the prostate bed following prostatectomy with or without treatment of the pelvic lymph nodes
- Hormone-sensitive prostate cancer
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
- Ability to understand the investigational nature, potential risks and benefits of the research study, and willingness to sign the written informed consent and HIPAA document(s)
- Willingness to fill out quality of life and psychosocial forms
- Willingness to participate in our institution's Prostate Cancer Database Protocol (ID# 20090767)
Exclusion Criteria:
- No pathological diagnosis of prostate adenocarcinoma
- Patient has more than 5 sites of metastatic disease
- Patient has history of bone and/or visceral metastasis
- No evidence of disease in the para-aortic lymph nodes
- No staging with PSMA PET/CT scan
- History of prior radiation therapy outside the pelvis for prostate cancer
- Bulky nodal disease >5 cm in tumor size
- Androgen deprivation therapy (ADT) or chemotherapy in the three months prior to staging PSMA PET/CT scan (suggesting oligoprogressive disease, rather than true oligorecurrent disease) or at time of study enrollment
- Suspicious radiologic evidence of disease in the prostate on staging PSMA PET/CT scan without confirmatory negative prostate biopsy
- Implanted hardware which limits treatment planning or delivery (determined by treating physician)
- Castration-resistant prostate cancer (history of rising PSA with serum testosterone level <50 ng/dL)
- Patients with ECOG performance status > 2
- History of inflammatory bowel disease
- History of malignancy other than prostate cancer except for non-melanoma skin cancer
- Patients unable to consent or are prisoners
- Unwilling to fill out quality of life and psychosocial forms
- Participants with impaired decision-making capacity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PSMA-Guided PA-RT Group
Participants in this group will undergo up to six months of systemic androgen deprivation therapy (ADT) and Androgen receptor signaling inhibitor (ARSI). During system therapy, participants will undergo five weeks of para-aortic radiation therapy. Total participation duration is up to five years. |
Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 50 grays (Gys) delivered in 25 fractions to the Clinical Tumor Volume (CTV).
Other Names:
Participants will undergo five weeks of PA-RT daily, for up to 30 minutes per day for 25 days, Monday through Friday, consisting of a total dose of 60 to 65 Gys delivered in 25 fractions to the Gross Tumor Volume (GTVn).
Other Names:
Androgen deprivation therapy will be administered as per standard of care.
Other Names:
Androgen receptor signaling inhibitor (ARSI) will be administered as per standard of care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS)
Time Frame: Up to 2 years
|
Progression-free survival (PFS) among participants will be assessed during treatment and clinical follow-up.
PFS is defined as the time from start of treatment until any of the following: Biochemical failure, escalation of therapy, radiological evidence of disease progression or death of any cause.
Radiological evidence of disease progression will be assessed by the treating physician using the Response Evaluation Criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) version 1.0.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biochemical Failure-Free Survival (FFS)
Time Frame: Up to 2 years
|
Biochemical failure-free survival among participants will be assessed during treatment and clinical follow-up.
Biochemical failure-free survival is defined as the time from study enrollment to time of biochemical failure.
Biochemical failure, as adapted from the Prostate Cancer Working Group 2 (PCWG2), is defined as when prostate-specific antigen (PSA) level increases ≥ 25% and ≥ 2 ng/mL above the nadir, which is confirmed by a second value obtained three or more weeks later.
|
Up to 2 years
|
Metastasis-Free Survival
Time Frame: Up to 2 years
|
Metastasis-free survival among participants will be assessed during treatment and clinical follow-up.
Metastasis-free survival is defined as the time from study enrollment to clinical or radiological evidence of metastatic disease or death.
|
Up to 2 years
|
Overall Survival (OS)
Time Frame: Up to 2 years
|
Overall survival (OS) among participants will be assessed.
OS is defined as the time from study enrollment to death of any cause.
|
Up to 2 years
|
Median Cause Specific Survival
Time Frame: Up to 2 years
|
Median case specific survival among participants will be assessed.
Median cause specific survival is defined as the time from study enrollment to death secondary to prostate cancer.
|
Up to 2 years
|
Proportion of Participants Undergoing Escalation of Therapy
Time Frame: Up to 2 years
|
The proportion of participants undergoing escalation of therapy will be reported.
Escalation of therapy is defined as subsequent course of radiation therapy or change in systemic therapy (except for intolerable side effects).
|
Up to 2 years
|
Proportion of Participants Experiencing Cumulative Late Grade ≥ 2 Treatment-Related Toxicity
Time Frame: Up to 2 years
|
The proportion of participants experience late grade ≥ 2 treatment related toxicity between 90 days and two years following para-aortic radiation therapy (PA-RT) will be reported.
Late toxicity is defined as Grade ≥ 2 treatment-related toxicities occurring more than 90 days after completing para-aortic radiation therapy (PA-RT).
The severity of the reactions to the treatment will be assessed according to using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
Up to 2 years
|
Change in Quality of Life Scores: EPIC 26 Short Form
Time Frame: Up to 2 years
|
Health-related Quality of Life (HRQOL) will be measured using the Expanded Prostate Cancer Index Composite 26 Short Form (EPIC-26) to evaluate patient function and satisfaction after prostate cancer treatment.
EPIC-26 is a short form version of the Expanded Prostate Cancer Index Composite, and is a validated comprehensive instrument developed to measure the health-related quality of life among men with prostate cancer.
EPIC-26 consists of 26 items under 5 domains of urinary incontinence, urinary irritative/obstructive, bowel, sexual, and hormonal.
Response options for each item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better HRQOL.
|
Up to 2 years
|
Change in Quality of Life Scores: HADS
Time Frame: Up to 2 years
|
Health-related Quality of Life (HRQOL) will be measured using the Hospital Anxiety and Depression Scale (HADS) questionnaire.
The HADS is a validated instrument used to measure patient symptoms of anxiety and depression.
The HADS questionnaire consists of six questions, three questions each in two domains, HADS-Anxiety and HADS-Depression.
Scores in each domain range from 0-9, with higher scores representing greater levels of anxiety and depression.
|
Up to 2 years
|
Change in Quality of Life Scores: IPSS
Time Frame: Up to 2 years
|
Health-related quality of life (HRQOL) will be measured using the International Prostate Symptom Score (IPSS) to evaluate patient urinary function and quality of life.
There are 7 questions related to urinary function.
Responses are on a scale from 0 ("not at all") to 5 ("almost always"), with higher scores indicating higher levels of urinary dysfunction.
There is one quality of life question related to urinary symptoms.
Responses are on a scale from 0 ("delighted") to 6 ("terrible").
Responses will be tabulated for a composite score.
|
Up to 2 years
|
Complete Early Response Rate
Time Frame: Up to 2 years
|
The Complete Early Response rate among participants will be reported.
Complete Early Response is defined as seen as on the 3-month post-PA-RT PSMA PET/CT scan using the Response Evaluation Criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) version 1.0; or a PSA level ≤ 0.1 ng/mL.
A composite of these two evaluations will be used to determine the complete early response rate.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Benjamin J Rich, MD, University of Miami
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protective Agents
- Estrogens
- Micronutrients
- Vitamins
- Antioxidants
- Anabolic Agents
- Ascorbic Acid
- Androgens
- Methyltestosterone
- Estrogens, Conjugated (USP)
Other Study ID Numbers
- 20231278
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on Para Aortic Radiation Therapy: Photon Therapy
-
Danish Breast Cancer Cooperative GroupRecruitingEarly Breast Cancer | Radiation Associated Cardiac FailureDenmark
-
Massachusetts General HospitalNational Cancer Institute (NCI); American Society of Clinical OncologyRecruitingMyocardial Fibrosis | Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage IIIUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingUnrectable or Locally Recurrent Hepatocellular CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institute of Dental and Craniofacial...Active, not recruitingStage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7United States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingSchwannoma | Grade III Meningioma | Intracranial Neoplasm | Nerve Sheath Neoplasm | Grade II Meningioma | Grade I Meningioma | Pituitary Gland AdenomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Lung Non-Small Cell Carcinoma | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7United States
-
Maastricht Radiation OncologyUniversity of Pennsylvania; Philipps University Marburg Medical Center; University...CompletedCarcinoma, Squamous Cell of Head and NeckNetherlands
-
Memorial Sloan Kettering Cancer CenterMayo ClinicRecruitingHead and Neck CancerUnited States
-
Technische Universität DresdenGerman Cancer Research Center; National Center for Radiation Research in Oncology...RecruitingNon-Small Cell Lung CancerGermany
-
Proton Collaborative GroupRecruiting